Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease.
about
Anti-dementia medications: current prescriptions in clinical practice and new agents in progressTau Biology and Tau-Directed Therapies for Alzheimer's DiseaseNeuroprotective Effects of the Herbal Formula B401 in Both Cell and Mouse Models of Alzheimer's Disease.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Conformational selection in amyloid-based immunotherapy: Survey of crystal structures of antibody-amyloid complexes.First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.Truncated tau deregulates synaptic markers in rat model for human tauopathy.Tau Proteins and Tauopathies in Alzheimer's Disease.Tauopathies: Mechanisms and Therapeutic Strategies."Tau immunotherapy: Hopes and hindrances".Tau hyperphosphorylation in synaptosomes and neuroinflammation are associated with canine cognitive impairment.Human Truncated Tau Induces Mature Neurofibrillary Pathology in a Mouse Model of Human Tauopathy.Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.A common antigenic motif recognized by naturally occurring human VH5-51/VL4-1 anti-tau antibodies with distinct functionalities.Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.Anxiolytic and antidepressant-like effects ofFerulago angulataessential oil in the scopolamine rat model of Alzheimer's diseaseTen Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead
P2860
Q26795400-FD7FB5B4-1312-48A6-A297-4415ECAFB215Q28071398-6B47E580-E00F-4C40-953A-CABB4CC06CE3Q37330022-829BB6F3-6FED-4CD2-97DA-832D265CAD03Q38715233-CFB8673D-3E17-4842-80BD-6DC8CB4AA690Q38856199-C887CBDD-2451-4062-A0FF-DAAD99C3F1F1Q39083050-40C79B9B-969C-42C8-80DD-A5CDD2B596CFQ41257772-E9C455FA-E390-47C7-9FD9-CB10F3F92C59Q47233523-A6B73A99-2356-469E-B711-A77534391A81Q47253592-E398E64F-CBBD-4CFD-AE0E-65FD82F6B87AQ47629452-6FDA023B-5B9A-40FE-B762-CCBF9906AAA4Q47949668-004382BF-B27A-414A-B904-E40522952172Q48547546-ACF1B460-5705-4945-A819-A8A5D63247E6Q50632272-3E48EE3A-4763-4CD3-844E-367CE9D2B583Q55238549-CF27B90D-6CAD-43EA-A98F-A017C76C7605Q55345450-92ADD377-FA50-442A-AD69-0E3D027E19CEQ57597893-4215E07E-26E7-4478-AA71-6409B1F244E4Q59137449-8C33062C-20C3-4BF3-8857-D6FFEA5387F9
P2860
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Identification of structural d ...... herapy in Alzheimer's disease.
@en
Identification of structural d ...... herapy in Alzheimer's disease.
@nl
type
label
Identification of structural d ...... herapy in Alzheimer's disease.
@en
Identification of structural d ...... herapy in Alzheimer's disease.
@nl
prefLabel
Identification of structural d ...... herapy in Alzheimer's disease.
@en
Identification of structural d ...... herapy in Alzheimer's disease.
@nl
P2093
P2860
P356
P1476
Identification of structural d ...... therapy in Alzheimer's disease
@en
P2093
Branislav Kovacech
Eva Kontsekova
Michal Novak
Norbert Zilka
P2860
P2888
P356
10.1186/ALZRT277
P407
P577
2014-08-01T00:00:00Z
P5875
P6179
1047897730